<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Selected studies reporting outcome of patients with surgically managed neuroendocrine liver metastases</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Selected studies reporting outcome of patients with surgically managed neuroendocrine liver metastases</h1>
<div class="graphic"><div class="figure"><div class="ttl">Selected studies reporting outcome of patients with surgically managed neuroendocrine liver metastases</div><div class="cntnt"><table cellspacing="0"><colgroup span="8" width="12%"></colgroup> <tbody> <tr> <td class="subtitle1">Study</td> <td class="subtitle1">Time period of study</td> <td class="subtitle1"> <p>Number of patients</p> <p>undergoing surgery</p> </td> <td class="subtitle1">Fraction undergoing combined modality therapy (resection + ablation) (%)</td> <td class="subtitle1">Symptom control (%)</td> <td class="subtitle1">5-year OS (%)</td> <td class="subtitle1">5-year recurrence rates (%)</td> <td class="subtitle1">10-year recurrence rates (%)</td> </tr> <tr> <td>Chamberlain (2000)<sup>[1]</sup></td> <td class="centered">1992-1998 </td> <td class="centered">34</td> <td class="centered">-</td> <td class="centered">54</td> <td class="centered">76 </td> <td class="centered">-</td> <td class="centered">- </td> </tr> <tr> <td>Elias (2003)<sup>[2]</sup></td> <td class="centered">1985-2000</td> <td class="centered">47</td> <td class="centered">- </td> <td class="centered">-</td> <td class="centered">71 </td> <td class="centered"> <p>5-year liver recurrence</p> <p>54</p> </td> <td class="centered"> <p>10-year liver recurrence</p> 75</td> </tr> <tr> <td>Sarmiento (2003)<sup>[3]</sup></td> <td class="centered">1977-1998</td> <td class="centered">170</td> <td class="centered">-</td> <td class="centered">96</td> <td class="centered">61</td> <td class="centered"> <p>84</p> </td> <td class="centered">94</td> </tr> <tr> <td>Osborne (2006)<sup>[4]</sup></td> <td class="centered">2000-2004</td> <td class="centered">61</td> <td class="centered">28</td> <td class="centered">93</td> <td class="centered"> <p>Mean</p> <p>43 months</p> </td> <td class="centered">-</td> <td class="centered">-</td> </tr> <tr> <td>Ahmed (2009)<sup>[5]</sup></td> <td class="centered">1973-2007</td> <td class="centered">50</td> <td class="centered">-</td> <td class="centered">-</td> <td class="centered">74</td> <td class="centered">-</td> <td class="centered">-</td> </tr> <tr> <td>Glazer (2010)<sup>[6]</sup></td> <td class="centered">1978-2009</td> <td class="centered">144</td> <td class="centered">16</td> <td class="centered">-</td> <td class="centered">77</td> <td class="centered">-</td> <td class="centered">-</td> </tr> <tr> <td>Mayo (2010)<sup>[7]</sup></td> <td class="centered">1985-2010</td> <td class="centered">339</td> <td class="centered">20</td> <td class="centered">-</td> <td class="centered">74</td> <td class="centered"> <p>94</p> </td> <td class="centered">99</td> </tr> <tr> <td>Saxena (2011)<sup>[8]</sup></td> <td class="centered">1992-2009</td> <td class="centered">74</td> <td class="centered">51</td> <td class="centered">-</td> <td class="centered">63</td> <td class="centered"> <p>79</p> </td> <td class="centered">86 (7 years)</td> </tr> <tr> <td>Gaujoux (2012)<sup>[9]</sup></td> <td class="centered">1992-2009</td> <td class="centered">36</td> <td class="centered">-</td> <td class="centered">60 (5-year symptom-free survival)</td> <td class="centered">69</td> <td class="centered"> <p>87</p> </td> <td class="centered">-</td> </tr> <tr> <td>Bagante (2017)<sup>[10]</sup></td> <td class="centered">1990-2014 </td> <td class="centered">376 </td> <td class="centered">22</td> <td class="centered">- </td> <td class="centered">-</td> <td class="centered">54  </td> <td class="centered">- </td> </tr> </tbody></table></div><div class="graphic_footnotes">OS: overall survival.</div><div class="graphic_reference">References: 

<ol>
<li>Chamberlain RS, Canes D, Brown KT, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 2000; 190:432.</li>
<li>Elias D, Lasser P, Ducreux M, et al. Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study. Surgery 2003; 133:375.</li>
<li>Sarmiento JM, HeywoodG, Rubin J, et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 2003; 197:29. </li>
<li>Osborne DA, Zervos EE, Strosberg J, et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol 2006; 13:572. </li>
<li>Ahmed A, Turner G, King B, et al. Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Endocr Relat Cancer 2009; 16:885. </li>
<li>Glazer ES, Tseng JF, Al-Refaie W, et al. Long-term survival after surgical management of neuroendocrine hepatic metastases. HPB (Oxford) 2010; 12:427. </li>
<li>Mayo SC, de Jong MC, Pulitano C, et al. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol 2010; 17:3129. </li>
<li>Saxena A, Chua TC, Sarkar A, et al., Progression and survival results after radical hepatic metastasectomy of indolent advanced neuroendocrine neoplasms (NENs) supports an aggressive surgical approach. Surgery 2011; 149:209. </li>
<li>Gaujoux S, Gonen M, Tang L, et al. Synchronous resection of primary and liver metastases for neuroendocrine tumors. Ann Surg Oncol 2012; 19:4270.</li>
<li>Bagante F, Spolverato G, Merath K, et al. Neuroendocrine liver metastases: The chance to be cured after liver surgery. J Surg Oncol 2017; 115:679.</li></ol></div><div id="graphicVersion">Graphic 97744 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
